Axonyx (AXYX) Quote

Historical Prices

Date Open High Low Close Volume AdjClose

2006/10/04 - - - - - -
2006/10/03 0.90 0.90 0.85 0.87 84,703 0.87
2006/10/02 0.89 0.92 0.88 0.90 76,326 0.90
2006/09/29 0.85 0.93 0.85 0.90 244,439 0.90
2006/09/28 0.88 0.91 0.85 0.90 53,218 0.90
2006/09/27 0.88 0.88 0.85 0.86 39,200 0.86
2006/09/26 0.87 0.92 0.85 0.88 45,769 0.88
2006/09/25 0.90 0.95 0.85 0.88 115,909 0.88
2006/09/22 0.93 0.93 0.89 0.92 58,564 0.92
2006/09/21 0.87 0.93 0.83 0.90 89,654 0.90
2006/09/20 0.97 0.97 0.90 0.90 52,618 0.90
2006/09/19 0.97 0.98 0.90 0.94 91,226 0.94
2006/09/18 0.98 0.99 0.97 0.99 31,755 0.99
2006/09/15 0.96 0.99 0.96 0.99 89,250 0.99
2006/09/14 0.98 0.98 0.96 0.98 144,757 0.98
2006/09/13 0.95 0.99 0.93 0.98 166,244 0.98
2006/09/12 0.97 1.01 0.95 1.00 406,761 1.00
2006/09/11 0.98 1.03 0.98 1.00 151,475 1.00
2006/09/08 0.97 1.01 0.97 1.01 47,752 1.01
2006/09/07 1.01 1.03 1.00 1.00 69,650 1.00
2006/09/06 0.95 1.04 0.95 1.00 190,034 1.00
2006/09/05 1.00 1.05 0.95 1.00 111,858 1.00
2006/09/04 1.00 1.02 1.00 1.02 73,439 1.02
2006/09/01 1.00 1.06 1.00 1.02 70,139 1.02
2006/09/01 1.00 1.06 1.00 1.02 73,439 1.02
2006/08/31 1.04 1.14 1.00 1.05 144,934 1.05
2006/08/30 0.96 9,600.00 0.91 1.01 239,129 1.01 << db error
2006/08/29 0.85 0.95 0.85 0.95 156,342 0.95
2006/08/28 0.85 0.88 0.85 0.86 237,605 0.86
2006/08/25 0.86 0.90 0.83 0.87 43,530 0.87
2006/08/24 0.86 0.88 0.85 0.86 19,009 0.86
2006/08/23 0.87 0.90 0.85 0.86 68,195 0.86
2006/08/22 0.86 0.89 0.85 0.87 87,778 0.87
2006/08/21 0.85 0.88 0.85 0.86 48,800 0.86
2006/08/18 0.86 0.87 0.84 0.85 161,977 0.85
2006/08/17 0.85 0.87 0.85 0.86 73,806 0.86
2006/08/16 0.86 0.87 0.85 0.85 143,763 0.85
2006/08/15 0.85 0.87 0.85 0.86 145,345 0.86
2006/08/14 0.85 0.86 0.85 0.85 87,077 0.85
2006/08/11 0.86 0.86 0.85 0.85 54,930 0.85
2006/08/10 0.85 0.87 0.85 0.86 14,708 0.86
2006/08/09 0.85 0.86 0.85 0.85 79,850 0.85
2006/08/08 0.85 0.87 0.85 0.85 98,711 0.85
2006/08/07 0.88 0.88 0.85 0.85 150,810 0.85
2006/08/04 0.88 0.89 0.86 0.88 31,210 0.88
2006/08/03 0.89 0.89 0.86 0.88 41,897 0.88
2006/08/01 0.86 0.88 0.85 0.86 74,907 0.86
2006/07/31 0.85 0.89 0.85 0.86 44,916 0.86
2006/07/28 0.85 0.88 0.85 0.85 131,560 0.85
2006/07/27 0.86 0.86 0.85 0.85 35,988 0.85
2006/07/26 0.89 0.89 0.85 0.86 39,270 0.86
2006/07/25 0.88 0.90 0.85 0.89 43,996 0.89
2006/07/24 0.85 0.88 0.85 0.88 53,067 0.88
2006/07/21 0.86 0.88 0.85 0.85 141,419 0.85
2006/07/20 0.87 0.88 0.85 0.86 72,938 0.86
2006/07/19 0.85 0.87 0.85 0.87 59,277 0.87
2006/07/18 0.85 0.87 0.83 0.85 210,868 0.85
2006/07/17 0.85 0.87 0.85 0.85 43,316 0.85
2006/07/14 0.85 0.87 0.85 0.85 77,704 0.85
2006/07/13 0.85 0.88 0.85 0.85 71,659 0.85
2006/07/12 0.85 0.89 0.85 0.85 55,477 0.85
2006/07/10 0.87 0.88 0.85 0.85 73,292 0.85
2006/07/07 0.87 0.87 0.85 0.87 64,990 0.87
2006/07/06 0.86 0.90 0.86 0.87 100,411 0.87
2006/07/05 0.86 0.89 0.85 0.86 214,790 0.86
2006/07/04 0.88 0.88 0.86 0.86 40,490 0.86
2006/07/03 0.85 0.88 0.85 0.86 40,490 0.86
2006/06/30 0.89 0.90 0.85 0.85 68,392 0.85
2006/06/28 0.88 0.89 0.83 0.86 233,451 0.86
2006/06/27 0.91 0.93 0.88 0.88 80,927 0.88
2006/06/26 0.94 0.94 0.91 0.91 96,200 0.91
2006/06/23 0.98 0.98 0.91 0.94 66,135 0.94
2006/06/22 0.99 0.99 0.95 0.98 51,002 0.98
2006/06/21 0.98 1.03 0.97 0.99 51,350 0.99
2006/06/20 1.03 1.04 0.98 0.98 42,694 0.98
2006/06/19 1.00 1.04 0.99 1.03 52,090 1.03
2006/06/16 0.96 1.04 0.96 1.00 147,840 1.00
2006/06/15 0.95 0.97 0.94 0.96 103,131 0.96
2006/06/14 0.95 0.97 0.92 0.95 214,908 0.95
2006/06/13 0.97 0.98 0.91 0.95 94,601 0.95
2006/06/12 0.96 1.00 0.92 0.97 229,840 0.97
2006/06/09 0.94 0.98 0.86 0.96 996,783 0.96
2006/06/08 0.95 0.99 0.80 0.94 1,332,027 0.94
2006/06/07 0.95 0.97 0.92 0.95 67,349 0.95
2006/06/06 0.94 0.97 0.92 0.95 207,747 0.95
2006/06/05 0.96 0.96 0.93 0.94 114,214 0.94
2006/06/02 0.95 0.98 0.93 0.96 112,835 0.96
2006/06/01 0.93 0.94 0.92 0.94 234,160 0.94
2006/05/31 0.93 0.95 0.92 0.93 236,796 0.93
2006/05/30 0.96 0.96 0.92 0.93 70,586 0.93
2006/05/29 0.99 0.99 0.96 0.96 82,687 0.96
2006/05/26 0.97 1.00 0.95 0.96 82,687 0.96
2006/05/25 0.94 0.98 0.92 0.97 122,815 0.97
2006/05/24 0.96 0.96 0.93 0.94 158,166 0.94
2006/05/23 0.96 0.97 0.95 0.96 237,383 0.96
2006/05/22 0.98 0.98 0.94 0.96 238,143 0.96
2006/05/19 1.02 1.03 0.98 0.98 496,916 0.98
2006/05/18 1.01 1.05 1.00 1.02 299,794 1.02
2006/05/17 1.03 1.07 1.01 1.01 300,141 1.01
2006/05/16 1.04 1.07 1.01 1.03 162,497 1.03

On June 8, 2006, Axonyx Inc. (Nasdaq: AXYX) and privately held
TorreyPines Therapeutics, Inc. announced that they have entered
into a definitive merger agreement. The resulting company
will be named TorreyPines Therapeutics, headquartered in San
Diego, California and traded on the NASDAQ Stock Market
under the proposed ticker symbol “TPTX.”


Terms

• Tax-free stock for stock merger
• Pro forma ownership of combined company
- Approximately 58% TorreyPines shareholders
- Approximately 42% Axonyx shareholders
- In addition, TorreyPines preferred shareholders receive
warrants to purchase combined company shares that, if
fully exercised at closing, give TorreyPines shareholders
approximately 62% of the combined company
- Relative percentages adjusted if either party out-licenses
one or more product candidates prior to closing
• Subject to customary and other closing conditions including
shareholder approval
• Transaction expected to close during the fourth quarter
of 2006
• Board of Directors to consist of five current TorreyPines
directors and three current Axonyx directors


ADVANTAGES OF THE AXONYX AND
TORREYPINES COMBINATION

• Robust and more diversified CNS pipeline to lower
development risk
• Combined company will have eight product candidates
- Novel parenteral and oral product candidates for pain
- Exceptional portfolio of six Alzheimer’s disease (AD)
product candidates
- Four of eight product candidates in the clinic
• Sufficient cash to advance multiple product candidates to
value-creating milestones
• Well capitalized – the pro forma combined company had
more than $80 million in cash at March 31, 2006
• Drug discovery capability to fuel ongoing product
development
• Established infrastructure and experienced leadership that
has a track record in bringing pharmaceuticals to market


UPCOMING MILESTONES

During the next 12 months, TorreyPines and Axonyx anticipate
several key milestones related to their product candidates.
Among these include the following:
• TorreyPines’ lead compound, tezampanel, is expected to
enter a Phase IIb clinical trial for the treatment of migraine
• TorreyPines expects to file an Investigational New Drug (IND)
application and then begin a Phase I trial for NGX426, the
oral prodrug of tezampanel and the company’s follow-on
compound for migraine and chronic pain
• Axonyx will complete its ongoing Phase I trials with
Posiphen™ for the treatment of AD progression
• Data will become available from TorreyPines’ Phase I
single dose study evaluating NGX267, the company’s
lead muscarinic agonist, in healthy elderly volunteers – a
population reflecting the age of the primary AD population
• TorreyPines plans to initiate a multiple dose Phase I safety
study with NGX267
• Axonyx to begin a Phase I clinical trial with BNC, its highly
selective butyrylcholinesterase inhibitor for the treatment of
severe AD

MANAGEMENT

Dr. Neil Kurtz, President and Chief Executive Officer

Dr. Kurtz is an accomplished clinician with more than 25 years
of global executive management experience in pharmaceutical
and healthcare provider companies. Prior to joining TorreyPines
Therapeutics, Dr. Kurtz co-founded Worldwide Clinical Trials, a contract
research organization, where he held the positions of President and
Chief Executive Officer until its acquisition by UnitedHealth Group
(UHG) in September 1999. After the acquisition, Dr. Kurtz became
President of Ingenix Pharmaceutical Services, a division of UHG, and
also served as a member of the UHG Executive Board until joining
TorreyPines Therapeutics. Dr. Kurtz’s career includes senior positions
with Boots Pharmaceuticals, Bayer Corporation, Bristol-Myers Squibb
Company, and Merck. Over the course of his career, Dr. Kurtz played
instrumental roles in numerous New Drug Applications (NDA)
submissions and successfully brought multiple pharmaceuticals to
market, including the anti-obesity drug Meridia®; Pepcid® for pain
related to stomach ulcers; and the anti-anxiety therapy BuSpar®.

Evelyn Graham, Chief Operating Officer

Prior to joining TorreyPines Therapeutics, Ms. Graham was Executive
Director, Development Operations at Purdue Pharma. In this capacity,
she managed global operations supporting a portfolio of marketed
and early to late-stage pain compounds. Ms. Graham has 19 years
clinical development experience and a proven track record of
establishing and running development operations for pharmaceutical
and contract research organizations. Ms. Graham was Senior Vice
President of Business Development at Ingenix Pharmaceutical
Services, a division of UnitedHealth Group (UHG), and Vice President of
Clinical Operations at Worldwide Clinical Trials, prior to its acquisition
by UHG. Her pharmaceutical experience includes positions in
operations management, healthcare utilization, and organizational
planning at Bayer Corporation and Wyeth Pharmaceuticals (formerly
Ayerst Laboratories).

Craig Johnson, Chief Financial Officer

Mr. Johnson has served as a senior financial executive in the biotech industry
for more than 10 years. Prior to joining TorreyPines Therapeutics, he was
Chief Financial Officer and Senior Vice President of Operations at MitoKor and
previously held financial management positions at several early-stage technology
companies. A Certified Public Account, Mr. Johnson began his career working for
the accounting firm Price Waterhouse LLP.

Dr. Michael Murphy, Chief Medical Officer

Prior to joining TorreyPines Therapeutics in 2004, Dr. Murphy was Chief
Medical and Scientific Officer for Ingenix Pharmaceutical Services, a division of
UnitedHealth Group (UHG), and he also served as liaison with other UHG business
units in matters of clinical trial design, regulatory activities and other programs of
research. Prior to its acquisition by UHG, Dr. Murphy was Vice President of Scientific
Affairs at Worldwide Clinical Trials. Previously, he served as Senior Vice President,
Worldwide Clinical Research at Cephalon, Inc., and Vice President, Scientific and
Professional Affairs, Neuroscience-Strategic Business Unit, at Hoechst-Roussel
Pharmaceuticals.

Dr. Steven Wagner, Chief Scientific Officer

Dr. Wagner co-founded TorreyPines Therapeutics, then named Neurogenetics,
in 2000 as its Chief Scientific Officer. Prior, Dr. Wagner was the Director of Protein
Biochemistry at SIBIA Neurosciences. He served as the program head of SIBIA’s
Alzheimer’s disease drug discovery collaboration with Bristol-Myers Squibb (BMS).
This collaboration resulted in the first gamma-secretase inhibitor for Alzheimer’s
disease to reach the clinic. Dr. Wagner was a member of SIBIA’s Strategic Planning
and Drug Discovery Steering Committees and a member of the Joint Steering
Committee between SIBIA and BMS. Dr. Wagner is an inventor on numerous
patents and patent applications and has published over 50 chapters and
research papers in the top scientific journals. Prior to leading SIBIA’s Alzheimer’s
disease drug discovery efforts, Dr. Wagner was a Research Associate Professor
in the Department of Microbiology and Molecular Genetics at the University of
California at Irvine where he co-authored the initial purification and identification
of the human amyloid precursor protein.

http://www.torreypinestherapeutics.com/images/uploads/TPTX-AXYX%20Fact%20Sheet_%20Final.pdf

EB: Rathoff has quite a few shares that he bought at open market prices, and he is underwater. He obviously did not think AXYX could survive on its own and sought the best solution he could come up with. It might take a little time, but I think this could be a profitable trade if you have a 1-2 years time horizon. I still think Posiphen has potential. Phenserine might have some potential, perhaps in combination with a drug to enhance cognitive abilities, such as those being worked on by Cortex (COR). In the meantime Torrey Pines has a migraine drug in later stage testing. They were cash poor, AXYX was progress challenged. AXYX wanted some bigPharma to partner with them and carry the financial load for further trials. That didn't come about. This deal was the best they could do. The stock has rebounded from its lows and is right back in the range it was in before the merger announcement. I have been disappointed in my AXYX investment so far, but I own several small fry biotechs to spread my risk. So I don't fret about it. I will hold and see where the merged company goes. We could be in for a surprise on the upside.

What do you think of Ratoff's inside purchases now and his insight into the company's future?

Merger Announced Today. Not enough details, but I have to think this is going to be a positive development going forward. I don't think any AXYX investor was happy with current management. I am sure Torrey Pines management will be in firm control after the merger. They have to be better than what we have now. The stock is rising from it's early low today as the news gets analyzed. It is dilutive to AXYX shareholders, but the combined company will have $80 million to work with. If progress can be made we can recoup our merger losses quickly. And Torrey Pines migraine drug looks like it has some potential. I'm going to hold for now and give the merger a chance to succeed. What do I have to lose at this point, 90 cents a share? Just a little above where I bought it late last year. It was a risk then. It is a risk now. I'll give them a year to see if there is any progress. I'm patient.

Has all interest been lost in this stock?

Does anyone know if there are going to be any PR coming out soon? It seems the market is losing interest in AXYX. They finished their phase 1 for Posiphen and Phenserine seems to have an affect on AD. Why is the stock been battered?

Axonyx Announces Completion of the Multiple-Dose Phase I Study of Posiphen(TM)
Monday May 15, 4:15 pm ET


NEW YORK--(BUSINESS WIRE)--May 15, 2006--Axonyx Inc. (NASDAQ: AXYX - News) announced today the completion of its second Phase I study with Posiphen(TM) in clinical development for the treatment of Alzheimer's disease progression.
ADVERTISEMENT


This double-blind, placebo-controlled multiple ascending-dose safety and pharmacokinetic study of Posiphen in healthy volunteers sought to establish well tolerated doses. The initial review of the clinical adverse event data appears to be generally consistent with the results of the earlier single ascending dose Phase I study that suggested that the mean Posiphen blood levels associated with well tolerated doses in humans are higher than those associated with potentially beneficial effects on beta-amyloid metabolism in animal models. The build-up of beta-amyloid (Aa) is generally believed to be causative of the dementia of Alzheimer's disease and its progression. No serious adverse events were reported at any dose level in this second Phase I study.

This multiple ascending-dose study examined the effects of Posiphen 20, 40 and 60mg given four times daily, for a period of 7, 7 and 10 days respectively. On the first and last day of each dosing period one single dose of Posiphen was given. Each dose period was completed and evaluated for safety and tolerance before the next higher dose level was initiated. Each cohort was composed of a different set of 16 subjects, comprised of 12 who received Posiphen and 4 who received placebo, with equal numbers of males and females in each.

The necessary detailed safety, pharmacokinetic and pharmacodynamic analyses are ongoing. Based on this favourable clinical outcome, Axonyx is evaluating plans regarding the further clinical development steps for Posiphen.

Posiphen(TM)

Current treatment of Alzheimer's disease focuses primarily on acetylcholinesterase inhibition. A major pathological hallmark of AD is the appearance of senile plaques that are primarily composed of aggregated forms of beta-amyloid (A beta) derived from beta-APP. Posiphen appears to modify the metabolism of beta-amyloid precursor protein (beta-APP). Soluble forms of A beta have been shown to cause significant toxicity in vitro and in vivo and hence represent a target for drug development in AD treatment.

The acetylcholinesterase (AChE) inhibitor Phenserine, which is currently in development by the Company mainly for the symptomatic treatment of mild to moderate AD, and its positive isomer, Posiphen, have both been found to significantly reduce beta-APP and A beta in cell culture systems and animals. As a consequence of its apparent lack of AChE inhibitory activity, Posiphen may be administered in relatively high doses. Such high doses may result in potentially meaningful reductions in A beta in Alzheimer's disease patients.

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders. The Company currently has three compounds in development for Alzheimer's disease, namely Phenserine - a potential symptomatic and disease progression treatment of mild to moderate Alzheimer's disease (AD), Posiphen(TM) - a potential disease progression treatment for AD now in Phase I, and BisNorCymserine (BNC) - a potential symptomatic treatment of severe AD now in pre-Investigational New Drug (IND) stage.

EB in GA: Ratoff is Chairman of the Board. I think he is the ultimate decision maker at this point. Dr. Bruinsma might be the CEO, but that is understandable with Axonyx's European presence. Bruinsma probably understands the science better, and can more effectively present the company's progress at conferences, etc. But Ratoff has a long track record in the pharmaceutical industry, and he knows how to maximize shareholder value if he has something to sell. I think he did pretty well when he sold little Cima Labs to Cephalon. He'll do the same for Axonyx if Phenserine and/or Posiphen show some good efficacy. Axonyx is not going to take either drug to market by itself. A partnership with bigPharma or an outright sale of the company to bigPharma is the goal. If the science is there, Ratoff will make money for the shareholders.

Ratoff is a director of the company. What makes you think he has that much individual control of the company spending?

Patience wil be rewarded. I've been out of town for 10 days and returned to see AXYX had dropped significantly since I bought more shares at $1.37. The drop in price is irrational in light of the very promising news the company reported in Geneva. Don't panic out there. Some mo-mo investors got in and then dumped. But the company has plenty of cash, and Rathoff is being careful with how he spends it. The 6 month PET scan results will probably re-confirm the effectiveness of the platform to reduce amyloid, and some memory efficacy will in all liklihood be demonstrated. I still see a nice potential upside, and I think we have a nice "floor" at @ $1.08. We should rise from here.

bigworld...

got in at 1.31 -now being patient. trust your judgement from the cygx bOARDS. Hope this board picks up some-yhaoo board is awful.

How low is this going to go? Starting to look like $1.00 is possible. I'm underwater and its getting deeper everyday.

Master: Rathoff had not been in place long enough. The previous management was primarily at fauly. Plus, the previous studies measured the effects subjectively and dose Phenserine too low to be beneficial for most of the study participants. By now utilizing PET scan imaging the drug's effects can be demonstrated conclusively. I think the six month evaluations at the institute in Sweden will further demonstrate this. But I understand your reluctance and the poor track record the company demonstrated last year. It is the main thing hindering progress in the stock price. But I have patience. I almost always make money on my biotechs. Not always a fortune, but I tend to buy really low and can then afford to ride the "waves". Thanks for your input.

That helps to explain the low confidence level on this price gain. I notice that Steve Ratoff is associated with another company, Novadell Pharma, NVD, and is also buying shares of that company also. PPS seems to be behaving better on this one. These purchases are more recent than his purchases of AXYX. Any one know what the connection between the companies is?

I was holding axyx when their phase III clinical trials came back as duds a year and a half ago. that took the stock from 5 dollars to barely one, after being at 8 a month earlier (i bailed a week before the trial results came back). management kept providing positive outlooks for their new drug only to see it fail. Class action suits up the wazoo after that. I, for one, am very skeptical of anything management has to say. trust has gone out the window, take everything with a grain of salt.

AXYX should be able to find a development partner for Phenserine after the recent finding. The market for Alzheimers is to big to ignore Phenserines potential. I would be disappointed if AXYX only hit $2.00 on a partnership announcement.

"There was a statistically significant increase in glucose metabolism as compared to baseline in the frontal and parietal cortical areas in the brains of Phenserine patients, while the placebo group did not show any significant changes from baseline. These observed changes were highly correlated with the statistically significant improvement in the Digit Symbol test of attention, an ability that resides in the frontal cortex. The accumulation of FDG is a direct measure of the metabolic activity of neurons and is known to change in parallel with neuronal function. Patients with AD have characteristic reductions in FDG measurements of regional brain activity, which are progressive and correlate to dementia severity."

I've seen some of your posts on the CYGX board. Alot of shares have changed hands the last few days so its going to be interesting to see if it can find a new support base. I'll continue to build my position no matter how it trades.

Thanks,
See ya, on the boards

Trade: Welcome to our I-hub thread of 2. Maybe more will join in. I think the market is missing the boat here. AXYX sits on over $50 million in cash. They have a CEO with a track record of success. Their leading drug candidates are showing tremendous promise to treat a disease that costs the USA billions of dollars in care and for which the current drug therapies are mediocre at best. After this weekend's presentations in Geneva the stock should be on a tear. It should have crossed the $2.00 price barrier at least. But I am patient. My average basis is just under $1.00. I will make a significant profit from this stock, it is just a matter of time. Good luck to us.

The current medical treatments for Alzheimers only help to delay or prevent symptoms from becoming worse for a limited time and may help control some behavioral symptoms. Phenserine has been shown to have two mechanisms of action: (1) the inhibition of the AChE enzyme, and (2) inhibition of the synthesis of A beta - a protein thought to be a potential cause of Alzheimer's disease and its progression. I just don't think the market has grasped the potential market for Phenserine.

Today's study of Posiphen showed the ability of transplanted human neuronal stem cells (HNSC) to differentiate into neurons in the brain area where they are needed. Posiphen could be used to treat an assortment of brain injuries in addition to Alzheimer's.

With All The Positive News Over the last 5 days, why is the stock stuck in its current rut? The PET scan results were certainly encouraging. With the potential market available to a really effective Alzheimers drug you'd think the stock would have crossed the $2.00 barrier with last week's news, at least. I've seen stocks get a bigger boost from pre-clinical results in rats. I still have confidence in Rathoff. I'm in for a lot of shares, and I have patience.